Diagnostics

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

With TGA approval, Optellum's AI platform arrives to help tackle Australia's low lung cancer survival rates by enabling earlier, more accurate detection.

With millions of Canadians suffering from dry eye, a new program combines advanced tech like IPL with personalized plans to offer hope and accessible relief.

A new skincare brand is skipping mass marketing, embedding its products with veterans, skiers, and melanoma researchers to redefine sun protection.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

A nonprofit is investing millions in a novel program to fast-track academic breakthroughs for neurological diseases from the lab to patients.

A new partnership brings AI voice analysis to home caregiving, promising proactive support for seniors but raising new questions about privacy in our living rooms.

IMO Health integrates a global rare disease database into EHRs, promising to shorten diagnosis times and accelerate vital research for millions.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

The professional information giant posted robust 2025 earnings while ramping up AI investment and navigating a pivotal CEO transition. Here's what it means.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.